Denifanstat showed tolerability and a favourable safety profile and most TEAEs were mild or moderate.

The open-label Phase 3 trial evaluated the safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne over a 40-week period. Denifanstat is being developed by Ascletis for acne in ...

HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study ( NCT06248008) evaluating ...

Almirall, S.A. (ALM) a global pharmaceutical company dedicated to medical dermatology announced today that China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

In A Nutshell Dissolving microneedle patches embedded with microscopic bubbles deliver three acne medications simultaneously, ...

Acne is a skin condition characterized by clogged pores. When pores get clogged, it causes red lesions — which you know as pimples — to form on the face or other areas of the body, especially those ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Picture this: You just got out of bed after a long night’s rest and you’re feeling super refreshed and ...

Previous associations between depression, suicidal behavior and the acne drug isotretinoin may be explained by presence of the acne itself, rather than treatment with the medication, according to ...

Almirall’s Seysara receives China NMPA approval for treatment of moderate-to-severe acne: Barcelona, Spain Saturday, January 31, 2026, 11:00 Hrs [IST] Almirall, S.A, a global ph ...